Loading...

Media is loading
 

Affiliations

Advocate Illinois Masonic Medical Center

Presentation Notes

Evidence Based Practice poster presentation at Elevating Nursing Excellence: Purpose, Profession, Passion; Advocate Health Midwest Region Nursing Research & Professional Development Conference 2024; November 13, 2024; virtual.

Abstract

Background

Chemotherapy is known to cause peripheral neuropathy (PN) in 30-60% of patients, with no effective treatments once symptoms occur. Chemotherapy-induced peripheral neuropathy (CIPN) can lead to treatment delays, dose reductions/discontinuation, poor treatment outcomes, and reduced function and quality of life. Cryotherapy is thought to limit circulation of chemotherapy into periphery limiting nerve damage. Prophylactic cryotherapy has been shown to reduce CIPN.

Purpose

PICOT: In adult cancer patients initiating chemotherapy (P), what is the effect of implementing an evidence-based cryotherapy intervention during chemotherapy treatments (I), compared with standard care (C), on patient-reported sensory peripheral neuropathy (toxicity symptom) (O) during chemotherapy treatment (T)?

Implementation plan

This evidence-based practice (EBP) implementation project guided by the Iowa Model (2018) was initiated at a 16-bed infusion clinic in Chicago that delivers chemotherapy based on Quality Oncology Practice Initiative (QOPI®) standards with toxicity monitoring. An implementation team, including manager, clinical nurses, providers, and product vendor, collaborated to review literature and create an evidence-based protocol for cryotherapy (FDA approved) to guide product storage, proper use, and patient education. Nurses were trained to apply gel-packs/sleeves 15 minutes before, during, and 15 minutes after, with pack-change every two hours. Patients received verbal and written cryotherapy information during orientation with option to participate.  A retrospective chart review was conducted to identify CIPN incidence without intervention. Cryotherapy was implemented in 2023.

Outcomes

At baseline (n=69, Q3&4 2022), many patients (n=44, 62%) reported CIPN with 54% (n=38) Grade 1 and 9% (n=6) Grade 2. During implementation, cold intolerance was a significant barrier to starting and maintaining cryotherapy. Post intervention (n=12), CIPN were reported less often (n=6, 50%) with all Grade 1, no Grade 2. Data collection continues.

Implications

Overall, results show cryotherapy reduced CIPN frequency and severity. Strategies to address cold tolerance are in progress to improve cryotherapy adherence and efficacy.

Document Type

Poster

Publication Date

11-13-2024


 

Share

COinS
 
Nov 13th, 12:00 AM

Freezing Chemo Induced Neuropathy in Its Tracks

Background

Chemotherapy is known to cause peripheral neuropathy (PN) in 30-60% of patients, with no effective treatments once symptoms occur. Chemotherapy-induced peripheral neuropathy (CIPN) can lead to treatment delays, dose reductions/discontinuation, poor treatment outcomes, and reduced function and quality of life. Cryotherapy is thought to limit circulation of chemotherapy into periphery limiting nerve damage. Prophylactic cryotherapy has been shown to reduce CIPN.

Purpose

PICOT: In adult cancer patients initiating chemotherapy (P), what is the effect of implementing an evidence-based cryotherapy intervention during chemotherapy treatments (I), compared with standard care (C), on patient-reported sensory peripheral neuropathy (toxicity symptom) (O) during chemotherapy treatment (T)?

Implementation plan

This evidence-based practice (EBP) implementation project guided by the Iowa Model (2018) was initiated at a 16-bed infusion clinic in Chicago that delivers chemotherapy based on Quality Oncology Practice Initiative (QOPI®) standards with toxicity monitoring. An implementation team, including manager, clinical nurses, providers, and product vendor, collaborated to review literature and create an evidence-based protocol for cryotherapy (FDA approved) to guide product storage, proper use, and patient education. Nurses were trained to apply gel-packs/sleeves 15 minutes before, during, and 15 minutes after, with pack-change every two hours. Patients received verbal and written cryotherapy information during orientation with option to participate.  A retrospective chart review was conducted to identify CIPN incidence without intervention. Cryotherapy was implemented in 2023.

Outcomes

At baseline (n=69, Q3&4 2022), many patients (n=44, 62%) reported CIPN with 54% (n=38) Grade 1 and 9% (n=6) Grade 2. During implementation, cold intolerance was a significant barrier to starting and maintaining cryotherapy. Post intervention (n=12), CIPN were reported less often (n=6, 50%) with all Grade 1, no Grade 2. Data collection continues.

Implications

Overall, results show cryotherapy reduced CIPN frequency and severity. Strategies to address cold tolerance are in progress to improve cryotherapy adherence and efficacy.

 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.